We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Motif Bio Plc | LSE:MTFB | London | Ordinary Share | GB00BVVT4H71 | ORD 0.01P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.50 | 0.40 | 0.55 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMMTFB
RNS Number : 2402B
Motif Bio PLC
31 March 2017
31 March 2017
Motif Bio plc
("Motif Bio" or the "Company")
Change of Registered Office
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces a change in its registered office. With immediate effect, its new registered office is: 27/28 Eastcastle Street, London W1W 8DH.
For further information please contact:
Motif Bio plc info@motifbio.com Graham Lumsden (Chief Executive Officer) Zeus Capital Limited (NOMAD & BROKER) Phil Walker/Giles Balleny Dominic Wilson +44 (0)20 3829 5000 Northland Capital Partners Limited (BROKER) Patrick Claridge/David Hignell John Howes/Rob Rees (Broking) +44 (0)20 3861 6600 Walbrook PR Ltd. (FINANCIAL +44 (0)20 7933 8780 or motifbio@walbrookpr.com PR & IR) Mob: +44 (0)7980 541 893 Paul McManus Mob: +44 (0)7900 608 002 Mike Wort MC Services AG (EUROPEAN IR) Raimund Gabriel +49 (0)89 210 2280
Notes to Editors:
Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials (Revive 1 and Revive 2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-1 is expected in the second quarter of 2017 and REVIVE-2 is on track for data readout in the second half of 2017.
This information is provided by RNS
The company news service from the London Stock Exchange
END
CROJBMATMBBJBIR
(END) Dow Jones Newswires
March 31, 2017 11:15 ET (15:15 GMT)
1 Year Motif Bio Chart |
1 Month Motif Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
